Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Citation

  • Authors: Culver, C., Sundqvist, A., Mudie, S., Melvin, A., Xirodimas, D., Rocha, S.
  • Year: 2010
  • Journal: Mol Cell Biol 30 4901-21
  • Applications: in vitro / siRNA / INTERFERin
  • Cell types:
    1. Name: HeLa
      Description: Human cervix epitheloid carcinoma cells
    2. Name: MCF 10A
      Description: Human breast adenocarcinoma cells
      Known as: MCF10A, MCF 10A
    3. Name: U-2 OS
      Description: Human bone osteosarcoma
      Known as: U2OS

Method

5nM siRNA

Abstract

NF-kappaB activation is a critical component in the transcriptional response to hypoxia. However, the underlying mechanisms that control its activity under these conditions are unknown. Here we report that under hypoxic conditions, IkappaB kinase (IKK) activity is induced through a calcium/calmodulin-dependent kinase 2 (CaMK2)-dependent pathway distinct from that for other common inducers of NF-kappaB. This process still requires IKK and the IKK kinase TAK1, like that for inflammatory inducers of NF-kappaB, but the TAK1-associated proteins TAB1 and TAB2 are not essential. IKK complex activation following hypoxia requires Ubc13 but not the recently identified LUBAC (linear ubiquitin chain assembly complex) ubiquitin conjugation system. In contrast to the action of other NF-kappaB inducers, IKK-mediated phosphorylation of IkappaBalpha does not result in its degradation. We show that this results from IkappaBalpha sumoylation by Sumo-2/3 on critical lysine residues, normally required for K-48-linked polyubiquitination. Furthermore, inhibition of specific Sumo proteases is sufficient to release RelA from IkappaBalpha and activate NF-kappaB target genes. These results define a novel pathway regulating NF-kappaB activation, important to its physiological role in human health and disease.

Go to